Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are enclosed. As you will see, all three reviewers express significant interest in your identification of Gep4 as the PGP phosphatase involved in cardiolipin biosynthesis. Consequently, all are broadly in favour of publication, pending appropriate revisionboth referees 1 and 2 in particular raise a number of concerns that will need to be addressed experimentally, as well as by modifications to the text.
In the light of the referees' positive recommendations, I would like to invite you to submit a revised version of the manuscript, addressing all the comments of all three reviewers. I should add that it is EMBO Journal policy to allow only a single round of revision. Acceptance of your manuscript will thus depend on the completeness of your responses included in the next, final version of the manuscript. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as a standard revision time, and as a matter of policy, we do not consider any competing manuscripts published during this period as negatively impacting on the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Given the nature of the requested revisions, I hope that you should have no problem meeting this three-month deadline, but should there be any unforeseen difficulties, please let me know.
Thank you for the opportunity to consider your work for publication. I look forward to your revision. General comments This is a very interesting work which has been systematically performed, is well structured and well presented. This study closes the gap in the cardiolipin biosynthetic pathway by identification of a PGP phosphatase. This work is a valuable contribution to our understanding of mitochondrial biogenesis.
Specific comments 1) The first part of the abstract is introductory and does not say much about the progress that has been made in this study. Tam41 is not explained. 2) Introduction: Tam41 evidence should be described in some more detail. 3) Page 6: It would be interesting to see the growth behaviour or strains bearing a defect in GEP4 on non fermentable carbon sources. 4) Page 8: It has to be explained what Gep1 is. 5) While the authors clearly show that Gep4 dephosphorylates PGP it could well be that this enzyme has broader substrate specificity. It would be interesting to see data with other phosphorylated substrates, e.g. PIP or similar derivatives or even artificial substrates. Such data would not challenge the role of Gep4 in CL synthesis but provide a broader view of enzymatic properties of this enzyme. 6) Fig. 7 and related text: This figure and the description make the reader feel that PA is exclusively derived from the action of Slc1 and Ale1. This is misleading because PA may come from other sources, too. Also, the role of Tam41 is rather vague. The authors should be a bit more cautious with this model. 7) In the Methods section the strains used should be listed and the growth conditions should be mentioned.
Referee #2 (Remarks to the Author):
A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4
Cardiolipin is a specific dimeric glycerophospholipid unique to mitochondria, which is crucial for respiratory metabolism. Defects in cardiolipin biogenesis cause a severe human disease called Barth syndrome. Even though the biogenesis of cardiolipin has been extensively studied for decades and most enzymes involved were identified more than 10 years ago, a single enzymatic step in eukaryotes has remained enigmatic. Osman et al. report about the identification of this phosphatidylglycerolphosphate (PGP) phosphatase:
Gep4 is localized in the mitochondrial matrix and peripherally attached to the inner membrane. Yeast cells lacking Gep4 or carrying a mutation in the phosphotransferase motif of Gep4 have destabilized respiratory chain supercomplexes and impaired cell growth at elevated temperatures, phenotypes characteristic for cardiolipin mutants. The authors show that in the absence of Gep4 a precursor lipid PGP accumulates and the cells concomitantly lack cardiolipin. Osman et al. show that Gep4 dephosphorylates PGP in vitro. Furthermore the authors show that the PGP phosphatase PgpA from E. coli targeted to mitochondria restores not only the growth defect, but also the cardiolipin deficiency caused by the lack of Gep4.
Osman et al. have identified the PGP phosphatase Gep4, which is essential for cardiolipin biogenesis. This is not only a very exciting contribution to the fields of mitochondrial and lipid biogenesis, but is also extremely important for the field of cellular bioenergetics and research concerning the Barth syndrome. In case the authors can address the specific points indicated below I recommend the publication of this manuscript in The EMBO Journal.
Major points:
The subcellular and submitochondrial localization is very crucial in order to assign a specific function to Gep4. 1: Therefore the authors should analyze a subcellular fractionation with the antibody against endogenous Gep4 to unambiguously show that Gep4 is exclusively localized to mitochondria. 2: In figure 2B the authors show an alkali extraction experiment. In comparison to the total the authors recover only a tiny fraction of Gep4-TAP in the pellet and soluble fractions. Only if one recovers a similar amount in the pellet and soluble fractions like in the total one can make a conclusion. In the figure the authors imply to perform the western blot against Gep4, but in the legend they write that they used a Gep4-TAP tagged strain. Since the authors have an antibody against endogenous Gep4 (see figure 2A) , they should perform this experiment with wildtype cells. 3: In Osman et al., JCB, 2009 the authors show that Gep4 has about 15% of cardiolipin compared to wildtype. In contrast in figure 3B the cardiolipin levels of deltagep4 are indistinguishable from delta crd1. In addition the authors write on page 17, that deltagep4 mitochondria contain low levels of PG. Therefore the authors must quantify the level of cardiolipin compared to wildtype and deltacrd1 mitochondria. 4: The authors state that phosphatidylethanolamine (PE) is slightly increased in deltagep4 mitochondria ( Figure 3A ). However the amount of Tom40 protein is concomitantly higher in the gep4 mutant mitochondria preparations. Therefore this could be a loading problem. In addition in figure 3B the lipids PI and PS are similarly increased and in figure 3C , 5D and 6C a higher level of PE is not apparent. Also in figure 4B the PE levels of deltagep4 mitochondria are not consistent. Additionally the authors write on page 16 '... PE levels are not increased in Pgs1-deficient mitochondria, but in cells lacking Crd1, Gep4, Ups1 or Tam41.' Unless the authors provide compelling evidence for all these yeast strains by a detailed quantification of PE compared to total phospholipids all paragraphs concerning this topic must be removed. 5: The authors should state in the manuscript if the Gep4 gene is related to one of the bacterial PGP phosphatase genes.
Minor points:
1: In the introduction the authors write that the PGP phosphatase is not identified. However it is important to mention that its enzymatic activity was already detected in mitochondria (Kelly and Greenberg, BBA, 1990) . 2: In the end of the introduction the authors write '...the last missing enzyme of the cardiolipin biosynthesis pathway in mitochondria.' This statement is not necessarily correct since a number of further gene products (some even identified by the authors themselves in Osman et al., JCB, 2009) are crucial for cardiolipin biosynthesis and could be enzymes or coenzymes. 3: In Figure 1C the authors should just show the area of interest for the Gep4-myc western blot. 4: The section about the genetic interaction of GEP4 and GEP1 is not convincing. A synthetic lethal interaction with GEP1 encoding an enzyme of unknown function does not support a role of Gep4 in maintaining normal CL levels. The authors write 'Cardiolipin deficient yeast cells cannot tolerate a reduction of PE levels'. However Gohil et al., JBC, 2005 report a specific synthetic lethal interaction of CRD1 and PSD1 and not with PSD2. 5: On page 12 the authors should refer to figure 4C instead of figure 4D . 6: The authors should enlarge the area of interest in figure 5D and label the lipid spots in WT and deltagep4. 6: On page 15 the authors write 'We observed an inability of deltagep4 cells to grow at elevated temperatures ... such phenotypes have been observed for cells lacking Pgs1 but not for cells lacking Crd1'. In several publications (Jiang et al., MM, 1999; Chen et al., MCB, 2008) it was shown that cells lacking Crd1 can not grow at elevated temperature. This sentence must be corrected. 7: First of all the authors should refer to figure 7 and additionally explain that MAM is a special subcompartment of the ER (this would improve the readability for the general audience of The EMBO Journal).
Referee #3 (Remarks to the Author):
In recent years, much progress has been made regarding the importance of cardiolipin and the steps involved in its synthesis, with many publications in the area in high quality journals. This unique phospholipid has been attributed to playing roles in maintenance of membrane protein complex assemblies, enzymatic function and general mitochondrial shape. Loss of cardiolipin has also been found to induce effects outside of the mitochondria including cell wall defects in yeast while defects in cardiolipin synthesis are also seen in patients with Barth syndrome. The manuscript by Osman and colleagues reports on the identification of a missing link in an enzymatic step in cardiolipin synthesis. Using a variety of technical and high quality experiments involving yeast genetics, mass spectrometric analysis and protein chemistry, the authors convincingly demonstrate that Gep4 is the phosphatase required for the synthesis of phosphatidylglycerol (PG) from phosphatidylglycerolphosphate (PGP). Using epistasis analysis, the authors also demonstrated that the recently identified Tam41 is also involved upstream of the enzymatic process. This work has high importance to the field of lipid biology and also general mitochondrial biology. While Gep4 is found in plants, it is absent from humans indicating that a different phosphatase is required. This aspect does impact on the overall significance of the findings yet the authors readily acknowledge this fact and they have the potential to identify this enzyme in the future using complementation techniques. The experiments are well controlled and the manuscript is well written. I only have a number of minor comments. 1. Introduction: "CL is ubiquitously distributed in bacteria and eukaryotic cells". This needs rewording since CL is mitochondrial-specific. 2. The authors should clarify more clearly how ethidium bromide treatment induces a growth phenotype. It has been previously shown by Zhong et al (2005) that the phenotype cause by EtBr treatment in cells with cardiolipin defects (lacking Pgs1) is due to cell wall defects and the defect can be stabilised by sorbitol treatment. 3. Page 11, reference is given of Figure 4D which in fact it should be Figure 4C . 4. Figure 7 has not been cited in the text and aspects of it should be integrated into the discussion (e.g. MAM and PA transport to the outer membrane). An additional arrow in Figure 7 indicating that CL may be transported to the OM would be useful given the recent study by Gebert et al (2009). Point-by-point response to the comments of the reviewers Reply to reviewer 1: 1) As suggested by the reviewer, we have modified the abstract, deleted an introductory sentence and added an explanatory sentence for Tam41.
2)
We describe now in more detail the current knowledge on Tam41 in the introduction on pp. 4/5.
3)
The growth of gep4 cells is impaired both on fermentable and non-fermentable carbon sources. We added a sentence on p. 6 and included a supplemental figure ( Figure S1 ).
4)
We introduce now Gep1/Ups2 on p. 8 of the manuscript. We also use now Ups2 (instead of Gep1) to be consistent with the standard yeast nomenclature.
5)
To further examine the specificity of the Gep4 phosphatase, we performed additional in vitro experiments using purified Gep4 and PI4P and PI4,5P as potential substrates, as suggested by the reviewer. As now shown in the supplemental figure S2 , neither PI4P nor PI4,5P (both not present in mitochondria in vivo) were dephosphorylated under the conditions used in our assay.
6)
We completely agree with the reviewer that it is currently unclear how PA is generated. We therefore modified our figure accordingly and also state in the text that different possibilities for the generation of PA exist. We also re-examined our wording concerning the role of Tam41 and tried to discuss as careful as possible potential functions of Tam41 in the discussion.
7)
We have listed all strains in the Supplementary table 1 and describe now the yeast strain background and growth conditions in the material and method section.
Reply to reviewer 2: 1)
We performed a cellular fractionation experiment using wild-type yeast cells and antibodies direct against endogenous Gep4. This experiment unambiguously demonstrates that Gep4 is enriched in the mitochondrial fraction. The available antibodies hardly recognize Gep4 in total cell lysates. As for any fractionation experiment, it is difficult to exclude the presence of minute amounts of Gep4 that escape immunodetection in non-mitochondrial fractions.
2)
We repeated the submitochondrial fractionation experiment (formerly Fig. 2B , now shown as Fig. 2C ) using wild-type yeast cells and antibodies direct against endogenous Gep4. We obtained identical results to the previous experiment using a tagged Gep4 variant, demonstrating that Gep4 is peripherally attached to the matrix-side of the mitochondrial inner membrane.
3)
We have repeatedly quantified CL and PG levels in wild-type, gep4 and crd1 mitochondria and show now the statistical evaluation of these experiments in Fig. 3B . The fact that the values for the CL concentration in gep4 mitochondria are slightly lower than in our previous report (that included a large number of mutant mitochondria) is likely explained by an improved technical routine and a larger number of experiments.
4)
Thin layer chromatography does not allow to monitor small differences in phospholipid levels in a reliable manner. We therefore determined PE levels by quantitative mass spectrometry in wild-type and Δgep4 mitochondria. These experiments (shown in Fig. 3B ) revealed a statistically significant increase in PE levels in the absence of Gep4. Therefore, we would like to briefly discuss implications of this observation in our manuscript, although this is certainly only a side-aspect. We agree that the PE levels in Δpgs1 mitochondria remain to be determined by mass spectroscopy and therefore use very careful wording in the discussion (p. 17) to comply with the concerns of the reviewer. We disagree, however, with the reviewer that the PE levels in Δgep4 mitochondria are not consistent in different figures. It should be noted that slight differences in the Tom40 levels seen in Fig. 3A cannot explain differences in the PE levels. We used the Tom40 immunoblotting in this experiment to establish similar expression of the Gep4 variants in the different strains. However, as stated in the material and method section, we performed phosphate quantifications after lipid extraction and prior to TLC analysis. The amount of phospholipids in the TLC analysis is therefore independent of the protein amount used for western blotting.
5)
Gep4 is not sequence-related to one of the bacterial PGP phosphatases, as now stated on p. 12.
Minor points: 1)
We refer now to the description of the PGP phosphatase activity in the mitochondrial fraction by Kelly and Greenberg (1990) in the introduction.
2)
We changed the wording of the sentence on p. 5.
3)
We would like to not change this figure to document absence of large molecular weight complexes containing Gep4 on BN-PAGEs.
4)
We agree with the reviewer that the observation of a genetic interaction of GEP1/UPS2 with GEP4 on its own does not represent sufficient evidence to establish a role of Gep4 for CL accumulation, but would like to keep these data as supportive evidence in the manuscript. We corrected the wording in the text to make clear that only a reduction of mitochondrial PE is deleterious for CL-deficient cells (in line with previous data from the Greenberg lab and our own genome-wide genetic screen).
5)
We have corrected the text accordingly.
6)
We have modified the figure as requested by the reviewer.
7)
We have corrected the mistake in this sentence.
8)
We refer now to Figure 7 in the discussion and introduced the MAM fraction to improve the readability for the general audience.
Reply to reviewer 3: 1)
We re-worded the sentence in the introduction to avoid misunderstandings.
2)
We describe now in more detail the basis for the ethidium bromide sensitivity of pgs1 cells in the discussion on p. 16.
3)
We have corrected the mistake on p. 11.
4)
We refer now to Figure 7 in the discussion and discuss now in more detail various aspects of the model in the text, to comply with the request of the reviewer. We also included an additional arrow in Fig. 7 (and a sentence in the figure legend) indicating that CL transport from the mitochondrial inner to the outer membrane must occur.
